{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:20:21Z","timestamp":1786980021692,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T00:00:00Z","timestamp":1562803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T00:00:00Z","timestamp":1562803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Astellas"},{"name":"Jannsen"},{"name":"Algorithm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s00345-019-02872-x","type":"journal-article","created":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T10:10:11Z","timestamp":1562839811000},"page":"681-693","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Management of patients with high-risk and advanced prostate cancer in the Middle East: resource-stratified consensus recommendations"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0192-5828","authenticated-orcid":false,"given":"Deborah","family":"Mukherji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassem","family":"Youssef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Dagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"El-Hajj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Nasr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Geara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Rabah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Al Dousari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabih","family":"Said","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Ashou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wassim","family":"Wazzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Farha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nibras","family":"Al Hamdani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousuf","family":"Al Hallaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Ghazal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifa","family":"Dbouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassel","family":"Bachir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement","family":"El Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghazi","family":"Sakr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hero K.","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Sayyid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Haidar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Zouain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar","family":"Bitar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Alameh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Faddoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Nemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Assaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Farhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Bulbul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Temraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Shamseddine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelius","family":"Omlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Khauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,11]]},"reference":[{"issue":"2","key":"2872_CR1","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.eururo.2017.06.002","volume":"73","author":"S Gillessen","year":"2018","unstructured":"Gillessen S et al (2018) Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017. Eur Urol 73(2):178\u2013211","journal-title":"Eur Urol"},{"issue":"4","key":"2872_CR2","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","volume":"67","author":"IR Diamond","year":"2014","unstructured":"Diamond IR et al (2014) Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol 67(4):401\u2013409","journal-title":"J Clin Epidemiol"},{"key":"2872_CR3","first-page":"1","volume":"4","author":"S Al-Sukhun","year":"2018","unstructured":"Al-Sukhun S et al (2018) ASCO resource-stratified guidelines: methods and opportunities. J Glob Oncol 4:1\u20138","journal-title":"J Glob Oncol"},{"issue":"6","key":"2872_CR4","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394\u2013424","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2872_CR5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.critrevonc.2013.11.001","volume":"90","author":"S Bazarbashi","year":"2014","unstructured":"Bazarbashi S et al (2014) Metastatic castration resistant prostate cancer: current strategies of management in the Middle East. Crit Rev Oncol Hematol 90(1):36\u201348","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"2872_CR6","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/cam4.549","volume":"5","author":"KA Herget","year":"2016","unstructured":"Herget KA et al (2016) Recent decline in prostate cancer incidence in the United States, by age, stage, and Gleason score. Cancer Med 5(1):136\u2013141","journal-title":"Cancer Med"},{"issue":"6 suppl","key":"2872_CR7","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1200\/JCO.2017.35.6_suppl.e552","volume":"35","author":"D Mukherji","year":"2017","unstructured":"Mukherji D et al (2017) Prostate cancer stage at diagnosis: first data from a Middle-Eastern cohort. J Clin Oncol 35(6 suppl):e552\u2013e552","journal-title":"J Clin Oncol"},{"issue":"19","key":"2872_CR8","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","volume":"378","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan V et al (2018) MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 378(19):1767\u20131777","journal-title":"N Engl J Med"},{"key":"2872_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cct.2015.02.008","volume":"42","author":"A El-Shater Bosaily","year":"2015","unstructured":"El-Shater Bosaily A et al (2015) PROMIS\u2013prostate MR imaging study: a paired validating cohort study evaluating the role of multi-parametric MRI in men with clinical suspicion of prostate cancer. Contemp Clin Trials 42:26\u201340","journal-title":"Contemp Clin Trials"},{"issue":"10162","key":"2872_CR10","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","volume":"392","author":"CC Parker","year":"2018","unstructured":"Parker CC et al (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392(10162):2353\u20132366","journal-title":"Lancet"},{"issue":"4","key":"2872_CR11","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND et al (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 377(4):338\u2013351","journal-title":"N Engl J Med"},{"issue":"10024","key":"2872_CR12","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James ND et al (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387(10024):1163\u20131177","journal-title":"Lancet"},{"issue":"8","key":"2872_CR13","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373(8):737\u2013746","journal-title":"N Engl J Med"},{"issue":"4","key":"2872_CR14","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K et al (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377(4):352\u2013360","journal-title":"N Engl J Med"},{"issue":"2","key":"2872_CR15","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/pros.22742","volume":"74","author":"G Gandaglia","year":"2014","unstructured":"Gandaglia G et al (2014) Distribution of metastatic sites in patients with prostate cancer: a population-based analysis. Prostate 74(2):210\u2013216","journal-title":"Prostate"},{"issue":"6","key":"2872_CR16","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.eururo.2014.07.004","volume":"66","author":"BR Viers","year":"2014","unstructured":"Viers BR et al (2014) Primary Gleason grade 4 at the positive margin is associated with metastasis and death among patients with Gleason 7 prostate cancer undergoing radical prostatectomy. Eur Urol 66(6):1116\u20131124","journal-title":"Eur Urol"},{"issue":"6","key":"2872_CR17","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(16)00111-X","volume":"17","author":"C Carrie","year":"2016","unstructured":"Carrie C et al (2016) Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol 17(6):747\u2013756","journal-title":"Lancet Oncol"},{"issue":"6","key":"2872_CR18","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.eururo.2015.12.010","volume":"69","author":"L Bianchi","year":"2016","unstructured":"Bianchi L et al (2016) The role of prostate-specific antigen persistence after radical prostatectomy for the prediction of clinical progression and cancer-specific mortality in node-positive prostate cancer patients. Eur Urol 69(6):1142\u20131148","journal-title":"Eur Urol"},{"issue":"15","key":"2872_CR19","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1200\/JCO.2006.08.9607","volume":"25","author":"AJ Stephenson","year":"2007","unstructured":"Stephenson AJ et al (2007) Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25(15):2035\u20132041","journal-title":"J Clin Oncol"},{"key":"2872_CR20","unstructured":"Fossati N et al (2017) Impact of early salvage radiation therapy in patients with persistently elevated or rising prostate-specific antigen after radical prostatectomy. Eur Urol"},{"issue":"3 Pt 1","key":"2872_CR21","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.juro.2016.08.106","volume":"197","author":"A Abugharib","year":"2017","unstructured":"Abugharib A et al (2017) Very early salvage radiotherapy improves distant metastasis-free survival. J Urol 197(3 Pt 1):662\u2013668","journal-title":"J Urol"},{"key":"2872_CR22","doi-asserted-by":"crossref","unstructured":"Perera M et al (2019) Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol","DOI":"10.1016\/j.eururo.2019.01.049"},{"issue":"5","key":"2872_CR23","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1607529","volume":"376","author":"WU Shipley","year":"2017","unstructured":"Shipley WU et al (2017) Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med 376(5):417\u2013428","journal-title":"N Engl J Med"},{"key":"2872_CR24","doi-asserted-by":"crossref","unstructured":"Rosenthal SA et al (2019) Effect of chemotherapy with docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer: the randomized phase III NRG oncology RTOG 0521 trial. J Clin Oncol JCO1802158","DOI":"10.1200\/JCO.18.02158"},{"issue":"13","key":"2872_CR25","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1002\/cncr.29983","volume":"122","author":"GA Viani","year":"2016","unstructured":"Viani GA et al (2016) Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: a randomized clinical trial. Cancer 122(13):2004\u20132011","journal-title":"Cancer"},{"issue":"6","key":"2872_CR26","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.prro.2018.08.002","volume":"8","author":"SC Morgan","year":"2018","unstructured":"Morgan SC et al (2018) Hypofractionated radiation therapy for localized prostate cancer: executive summary of an ASTRO, ASCO, and AUA evidence-based guideline. Pract Radiat Oncol 8(6):354\u2013360","journal-title":"Pract Radiat Oncol"},{"issue":"4","key":"2872_CR27","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.eururo.2018.06.018","volume":"74","author":"A Nabid","year":"2018","unstructured":"Nabid A et al (2018) Duration of androgen deprivation therapy in high-risk prostate cancer: a randomized phase III trial. Eur Urol 74(4):432\u2013441","journal-title":"Eur Urol"},{"issue":"1","key":"2872_CR28","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13014-017-0884-y","volume":"12","author":"FB Geara","year":"2017","unstructured":"Geara FB et al (2017) Nadir PSA is a strong predictor of treatment outcome in intermediate and high risk localized prostate cancer patients treated by definitive external beam radiotherapy and androgen deprivation. Radiat Oncol 12(1):149","journal-title":"Radiat Oncol"},{"issue":"26","key":"2872_CR29","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMe1805733","volume":"378","author":"MR Smith","year":"2018","unstructured":"Smith MR, Yu MK, Small EJ (2018) Apalutamide and metastasis-free survival in prostate cancer. N Engl J Med 378(26):2542","journal-title":"N Engl J Med"},{"issue":"26","key":"2872_CR30","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","volume":"378","author":"M Hussain","year":"2018","unstructured":"Hussain M et al (2018) Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 378(26):2465\u20132474","journal-title":"N Engl J Med"},{"issue":"13","key":"2872_CR31","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","volume":"380","author":"K Fizazi","year":"2019","unstructured":"Fizazi K et al (2019) Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 380(13):1235\u20131246","journal-title":"N Engl J Med"},{"issue":"5","key":"2872_CR32","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1093\/annonc\/mdy072","volume":"29","author":"MR Sydes","year":"2018","unstructured":"Sydes MR et al (2018) Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol 29(5):1235\u20131248","journal-title":"Ann Oncol"},{"key":"2872_CR33","unstructured":"Aguiar PN, Jr et al (2019) Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer. Einstein (Sao Paulo) 17(2):eGS4414"},{"issue":"11","key":"2872_CR34","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos CE et al (2018) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol 36(11):1080\u20131087","journal-title":"J Clin Oncol"},{"issue":"14","key":"2872_CR35","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1200\/JCO.2017.76.4381","volume":"36","author":"RZ Szmulewitz","year":"2018","unstructured":"Szmulewitz RZ et al (2018) Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer. J Clin Oncol 36(14):1389\u20131395","journal-title":"J Clin Oncol"},{"issue":"24","key":"2872_CR36","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","volume":"36","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal R et al (2018) Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J Clin Oncol 36(24):2492\u20132503","journal-title":"J Clin Oncol"},{"issue":"1","key":"2872_CR37","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00198-016-3766-5","volume":"28","author":"M Chakhtoura","year":"2017","unstructured":"Chakhtoura M et al (2017) The FRAX-based Lebanese osteoporosis treatment guidelines: rationale for a hybrid model. Osteoporos Int 28(1):127\u2013137","journal-title":"Osteoporos Int"},{"issue":"9768","key":"2872_CR38","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377(9768):813\u2013822","journal-title":"Lancet"},{"issue":"3","key":"2872_CR39","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3816\/CGC.2002.n.016","volume":"1","author":"F Saad","year":"2002","unstructured":"Saad F (2002) Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone. Clin Prostate Cancer 1(3):145\u2013152","journal-title":"Clin Prostate Cancer"},{"issue":"11","key":"2872_CR40","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/jnci\/djh141","volume":"96","author":"F Saad","year":"2004","unstructured":"Saad F et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96(11):879\u2013882","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2872_CR41","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/jama.2016.19425","volume":"317","author":"AL Himelstein","year":"2017","unstructured":"Himelstein AL et al (2017) Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. JAMA 317(1):48\u201358","journal-title":"JAMA"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-019-02872-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-019-02872-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-019-02872-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T19:50:39Z","timestamp":1594324239000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-019-02872-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,11]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["2872"],"URL":"https:\/\/doi.org\/10.1007\/s00345-019-02872-x","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,11]]},"assertion":[{"value":"21 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"D Mukherji: research funding\/honoraria from Astellas, Janssen, and Sanofi. A. Shamseddine: research funding\/honoraria from Astellas, Janssen, and Sanofi. R. Khauli: research funding\/honoraria from Astellas, Janssen, Hickma, and Algorithm. S. Gillessen: advisory role (including IDMCs) and Speakers Bureau: AAA International, Active Biotech, Amgen, Astellas Pharma, Bayer, Bristol-Myers Squibb, CellSearch, Clovis, CureVac, Dendreon, ESSA Pharmaceuticals, Ferring, Innocrin Pharmaceuticals, Janssen Cilag, MaxiVAX SA, Millenium, Nectar, Novartis, Orion, Pfizer, ProteoMediX, Roche, and Sanofi. Co-inventor on patent application (WO 2009138392 A1) for a method for biomarker discover (granted in China, Europe, Japan and the US). Deputy of the ESMO guidelines committee for GU cancers, member of the EAU guideline panel for prostate cancer, past chair of the EORTC GU group. Member of the STAMPEDE trial management group. All the other authors have no relevant conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}}]}}